Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Common Equity (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Common Equity for 15 consecutive years, with -$4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 13.13% year-over-year to -$4.5 million, compared with a TTM value of -$4.5 million through Sep 2025, up 13.13%, and an annual FY2024 reading of -$5.9 million, up 49.48% over the prior year.
  • Common Equity was -$4.5 million for Q3 2025 at Fennec Pharmaceuticals, up from -$7.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $24.9 million in Q1 2021 and bottomed at -$11.6 million in Q4 2023.
  • Average Common Equity over 5 years is $1.2 million, with a median of -$3.5 million recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 194.68% in 2021, then tumbled 475.84% in 2023.
  • Year by year, Common Equity stood at $19.0 million in 2021, then tumbled by 113.51% to -$2.6 million in 2022, then plummeted by 352.39% to -$11.6 million in 2023, then soared by 49.48% to -$5.9 million in 2024, then increased by 23.5% to -$4.5 million in 2025.
  • Business Quant data shows Common Equity for FENC at -$4.5 million in Q3 2025, -$7.5 million in Q2 2025, and -$5.9 million in Q1 2025.